Janni W, Dent RA, Schmid P. Rethinking First-Line Therapy and Beyond: HER2-Positive and Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer-Commentary Based on a Live Symposium Presented at the 2025 ESMO Congress in Berlin, Germany. Clin Breast Cancer 2025;26:100-104.
PMID: 41443030